Immune checkpoint inhibitor–induced inflammatory arthritis as a model of autoimmune arthritis

Research output: Contribution to journalReview articlepeer-review

Abstract

The development of inflammatory arthritis in patients receiving immune checkpoint inhibitor therapy is increasingly recognized due to the growing use of these drugs for the treatment of cancer. This represents an important opportunity not only to define the mechanisms responsible for the development of this immune-related adverse event and to ultimately predict or prevent its development, but also to provide a unique window into early events in the development of inflammatory arthritis. Knowledge gained through the study of this patient population, for which the inciting event is known, could shed light into the pathogenesis of autoimmune arthritis. This review will highlight the clinical and immunologic features of these entities to define common elements for future study.

Original languageEnglish (US)
Pages (from-to)106-123
Number of pages18
JournalImmunological reviews
Volume294
Issue number1
DOIs
StatePublished - Mar 1 2020

Keywords

  • autoimmunity
  • cancer
  • immune checkpoint inhibitor
  • immune-related adverse event
  • rheumatoid arthritis
  • spondyloarthropathy

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Fingerprint Dive into the research topics of 'Immune checkpoint inhibitor–induced inflammatory arthritis as a model of autoimmune arthritis'. Together they form a unique fingerprint.

Cite this